Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported late on Sunday that its preliminary fourth quarter revenues rose 64 percent year over year thanks to 66 percent growth in the number of completed Cologuard colorectal cancer diagnostic tests during the quarter.

For the three months ended Dec. 31, 2018, the company expects to report revenues of $142.5 million to $143.5 million, and said it completed approximately 292,000 Cologuard tests. Analysts are expecting revenues of $127.0 million for the quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.